US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

16.25 +0.21 (+1.31%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
News headline image
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity ↗
Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile. 
Via Benzinga
News headline image
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Cullinan Oncology: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Recap: Cullinan Oncology Q3 Earnings ↗
 
Via Benzinga
News headline image
Analyst Ratings for Cullinan Oncology ↗
 
Via Benzinga
Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Cullinan Oncology ↗
 
Via Benzinga
News headline image
Analyst Expectations for Cullinan Oncology's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Cullinan Oncology ↗
 
Via Benzinga
News headline image
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 ↗
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter. 
Via Benzinga
News headline image
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗
 
Via Benzinga
News headline image
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
 
Via Benzinga
News headline image
Why Shares of Cullinan Oncology Jumped This Week ↗
The company's presentation at a conference got the attention of analysts and investors. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >